M. Rowley

Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.

B. V. Van Ness, P. Liu, M. Rowley, 2000, Blood.

The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells.

D. Largaespada, B. V. Van Ness, S. Wiesner, 2007, Leukemia research.

Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response

B. Ness, M. Rowley, Matthew A Rowley, 2002, Oncogene.